PathVisio Analysis: An Application Targeting the miRNA Network Associated with the p53 Signaling Pathway in Osteosarcoma

Mervin Burnett,Consolato Sergi,David D Eisenstat,Roger Leng,Vito Rodolico,Mingyong Zhang,Fan Shen

doi:10.32604/biocell.2021.013973

Mervin Burnett, Consolato Sergi + Show 5 more

Open Access

https://doi.org/10.32604/biocell.2021.013973

Copy DOI

Journal: Biocell	Publication Date: Jan 1, 2021
Citations: 1	License type: cc-by

Affiliation: Stollery Children's Hospital, Wuhan University

Abstract

MicroRNAs (miRNAs) are small single-stranded, non-coding RNA molecules involved in the pathogenesis and progression of cancer, including osteosarcoma. We aimed to clarify the pathways involving miRNAs using new bioinformatics tools. We applied WikiPathways and PathVisio, two open-source platforms, to analyze miRNAs in osteosarcoma using miRTar and ONCO.IO as integration tools. We found 1298 records of osteosarcoma papers associated with the word “miRNA”. In osteosarcoma patients with good response to chemotherapy, miR-92a, miR- 99b, miR-193a-5p, and miR-422a expression is increased, while miR-132 is decreased. All identified miRNAs seem to be centered on the TP53 network. This is the first application of PathVisio to determine miRNA pathways in osteosarcoma. MiRNAs have the potential to become a useful diagnostic and prognostic tool in the management of osteosarcoma. PathVisio is a full pathway editor with the potentiality to illustrate the biological events, augment graphical elements, and elucidate all the physical structures and interactions with standard external database identifiers.

Highlights

Osteosarcoma (OS) is the most common primary malignant bone tumor, comprising about 20% of primary bone sarcomas
We found 1298 records of osteosarcoma papers associated with the word “miRNA”
Three studies were substantially selected from which miRNAs associated with osteosarcoma were used for further detailed analysis (Chen et al, 2016a; Kobayashi et al, 2012; Nugent, 2014)

Summary

Introduction

Osteosarcoma (OS) is the most common primary malignant bone tumor, comprising about 20% of primary bone sarcomas. It is a high-grade malignant tumor characterized by the cells forming immature bone or osteoid. The tumor is considered primary when the underlying bone is normal and secondary when it is altered by a pre-existing condition such as prior irradiation or Paget disease (Osasan et al, 2016; Sergi and Zwerschke, 2008). OS is usually associated with Paget disease of the bone, post-radiation sarcoma, and dedifferentiated chondrosarcomas (Sergi and Zwerschke, 2008).

Objectives

Methods

Results

Conclusion